ZARVY

Dapasmart M 10/500mg is a combination medication for Type 2 diabetes management, developed by Healing Pharma. It contains Dapagliflozin 10mg (an SGLT-2 inhibitor) and Metformin 500mg (a first-line diabetes treatment). This dual-action therapy lowers blood sugar levels by inhibiting glucose production in the liver and increasing glucose excretion through urine. Additionally, it supports weight management, cardiovascular protection, and potential liver health benefits.

Oxramet XR 10/500mg is an extended-release (XR) medication for Type 2 diabetes management, developed by Sun Pharmaceutical Industries Ltd. It combines Dapagliflozin 10mg (an SGLT-2 inhibitor) and Metformin 500mg (a first-line diabetes treatment) in an extended-release formulation. This dual-action therapy effectively lowers blood sugar levels by enhancing insulin sensitivity, reducing glucose production in the liver, and increasing glucose excretion through urine. The XR formulation ensures gradual absorption, minimizing gastrointestinal side effects commonly associated with Metformin.

Dapasmart M 10/1000mg is a combination therapy for Type 2 diabetes management, containing Dapagliflozin 10mg (SGLT-2 Inhibitor) and Metformin 1000mg (First-Line Therapy). This dual-action medication improves Glycemic Control by enhancing insulin sensitivity, reducing glucose production in the liver, and increasing glucose excretion through urine. Dapasmart M 10/1000mg also supports weight management, helps lower the risk of Cardiovascular Diseases, and may provide Liver Health benefits by improving hepatic glucose metabolism.

Oxramet S XR 500 is a combination therapy for Type 2 Diabetes, containing Dapagliflozin (SGLT-2 Inhibitor) 10mg, Sitagliptin (DPP-4 Inhibitor) 100mg, and Metformin (First-Line Therapy) 500mg. This triple-action formula effectively lowers blood sugar levels by enhancing insulin sensitivity, reducing hepatic glucose production, and increasing glucose excretion through urine. As part of a comprehensive diabetes management strategy, Oxramet S XR 500 improves Glycemic Control, helps prevent Cardiovascular Diseases, and supports Liver Health by regulating hepatic glucose metabolism. This extended-release (XR) formulation ensures gradual absorption, reducing gastrointestinal side effects commonly associated with Metformin.

Oxramet S XR 1000 is a triple-action therapy for Type 2 Diabetes management, combining Dapagliflozin (SGLT-2 Inhibitor) 10mg, Sitagliptin (DPP-4 Inhibitor) 100mg, and Metformin (First-Line Therapy) 1000mg. This formulation improves Glycemic Control by enhancing insulin sensitivity, reducing hepatic glucose production, and increasing glucose excretion through urine. As a once-daily extended-release (XR) tablet, Oxramet S XR 1000 provides long-lasting blood sugar regulation, helps prevent Cardiovascular Diseases, and supports metabolic stability. Additionally, Metformin plays a key role in promoting Liver Health by reducing hepatic glucose output and enhancing fat metabolism.

Bigomet 850mg is a generic oral medication containing Metformin 850mg, a widely prescribed first-line therapy for managing Type 2 Diabetes Mellitus. As part of the biguanide class of antidiabetic drugs, Metformin helps regulate blood sugar levels effectively without causing weight gain, making it a preferred choice for long-term diabetes management. Bigomet 850mg works primarily by reducing hepatic glucose production and enhancing insulin sensitivity, which allows the body to utilize glucose more efficiently. It also improves glucose uptake in muscle tissues and decreases the absorption of glucose from the intestines, resulting in better overall glycemic control. In addition to its glucose-lowering effects, Metformin is associated with weight management benefits, making it popular among patients who struggle with obesity-related diabetes. It also has cardiovascular protective effects, reducing the risk of heart disease in diabetic patients.

Bigomet 500mg is a widely prescribed antidiabetic medication. It contains Metformin 500mg, a first-line treatment for Type 2 diabetes mellitus. As a biguanide-class medication, it works by reducing glucose production in the liver, enhancing insulin sensitivity, and decreasing glucose absorption in the intestines. This non-insulin therapy is effective in controlling blood sugar levels, preventing complications, and offering additional benefits in weight management, cardiovascular protection, and metabolic health.

Bigomet SR 1000 is a sustained-release (SR) formulation of Metformin. It is used as a first-line treatment for Type 2 diabetes mellitus. The SR formulation allows for gradual absorption, reducing the risk of gastrointestinal discomfort while maintaining stable blood sugar levels. It helps improve insulin sensitivity, lower glucose production in the liver, and decrease glucose absorption from the intestines. In addition to diabetes management, Metformin is also known for its cardiovascular benefits, weight management support, and potential role in metabolic syndrome treatment.